Ranibizumab

Scheme

USAN

ATC (Anatomical Therapeutic Chemical Classification)

S01LA04

CAS registry number (Chemical Abstracts Service)

0347396-82-1

Chemical Formula

C2158-H3282-N562-O681-S12

Molecular Weight

48349

Therapeutic Categories

Monoclonal antibody

Ophthalmic agent for treatment of neovascular (wet) age-related macular degeneration

Angiogenesis inhibitor

Vascular Endothelial Growth Factor (VEGF) antagonist

Chemical Name

immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human - mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain (USAN)

Foreign Names

• Ranibizumabum (Latin)
• Ranibizumab (German)
• Ranibizumab (French)
• Ranibizumab (Spanish)

Generic Names

• Ranibizumab (OS: USAN, BAN)
• AMD Fab (IS: Genentech)
• rhuFab V2 (IS)

Brand Names

• Lucentis
  Genentech, United States; Novartis, Australia; Novartis, Belgium; Novartis, Canada; Novartis, Switzerland; Novartis, Germany; Novartis, Spain; Novartis, France; Novartis, United Kingdom; Novartis, Greece; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Italy; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Sweden; Novartis, Slovenia; Novartis Europharm, Austria; Novartis Europharm Ltd., Denmark; Novartis Pharmaceuticals, Peru

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.